via Doherty Institute
Australian scientists have discovered how the immune system can control melanoma, a mechanism which could be used to enhance cancer treatments.
Published today in Nature, Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Telethon Kids Institute researchers investigated the role of a particular immune cell, tissue-resident memory T (TRM) cells, in controlling melanoma.
TRM cells were able to control the tumour in the mice for the life of the animal, which is likely to equate to decades of protection in humans.
University of Melbourne PhD student, Simone Park from the Doherty Institute, created an imaging model to study TRM cells’ and melanoma in a mouse model.
“Using a special microscope, we could see individual melanoma cells sitting in the skin of the mouse, and could watch the T cells move through the skin, find the melanoma cells and control the growth of those cells,” Ms Park explained.
One of the main issues for cancer patients is that there is always a risk that the tumour can come back years later, after surgery or chemotherapy.
Previous research has shown that small numbers of cancer cells persist in the body after treatment and that the immune system probably keeps the cancer cells under control but this study in mice could study the immune system directly. This is work that could never be done in people.
“I was able to see through moving images that these TRM cells are important for maintaining the control of the tumour cells; if you remove the TRM cells you have a break in that control and the cancer can start to grow back again,” Ms Park said.
“If you could make more of these TRM cells through immunotherapies, or enhance the activity of those that are already there in some way, you could boost anti-tumour immunity.”
Senior author on the paper, University of Melbourne Associate Professor Thomas Gebhardt, Laboratory Head at the Doherty Institute, said an increase of TRM cells has already been associated with better outcomes in cancer patients, but the way they work to suppress tumours has remained unknown.
“The principal of cutting-edge immunotherapies currently in clinical practise is that they generate a T-cell response. But if we can hone in on one type of T-cell – the TRM cells specifically, we could have an even bigger impact on stopping cancers from coming back,” Associate Professor Gebhardt said.
“We now have a much better understanding of which T-cells are important in controlling skin cancers and how those cells are working but there is still much more work to do to make these cells work even better,” Associate Professor Gebhardt said.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- FDA Approves Adjuvant Keytruda for Pediatric and Adult Melanomaon December 3, 2021 at 4:21 pm
The FDA approved adjuvant Keytruda for patients ages 12 and older with stage IIB, IIC or III melanoma that has been completely resected.
- FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanomaon December 3, 2021 at 2:42 pm
The FDA has granted approval to pembrolizumab (Keytruda) for the adjuvant treatment of both adult and pediatric patients aged 12 years and older with stage IIB or IIC melanoma following complete ...
- FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanomaon December 3, 2021 at 1:43 pm
On December 3,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of adult and pediatric (≥12 years of age) patients with stage IIB or IIC ...
- Study shows difference in outcomes for women treated with checkpoint inhibitors for melanomaon December 2, 2021 at 7:00 pm
A class of cancer immunotherapy called checkpoint inhibitors has revolutionized cancer treatment. It's a new way to attack the disease by unleashing the immune system.
- Tebentafusp Represents a Potential Frontline Therapy for Patients with Uveal Melanomaon December 2, 2021 at 12:03 pm
Richard D. Carvajal, MD, discusses the need for additional treatment options in patients with rare melanomas, the promise of tebentafusp, and ongoing trials in the pipeline for this patient population ...
- Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanomaon December 2, 2021 at 10:02 am
Designation covers UV1 in Metastatic Melanoma as sole agent or part of combination ; Seven-year market exclusivity after regulatory approval, if received; Oslo, 2 December 2021: U ...
- Patient-led melanoma surveillance is safe, feasibleon December 2, 2021 at 6:42 am
Patient-led surveillance following melanoma surgery was safe and feasible, according to a pilot study. “After surgical excision of localized melanoma, patients are recommended to undergo long-term ...
- Researchers discover a new mechanism involved in early melanoma metastasison November 26, 2021 at 7:01 am
Research led by CNIO scientist Héctor Peinado shows that the NGFR molecule drives the entire process of early metastasis in melanoma and that blocking it drastically reduces metastasis in animal ...
- Researchers uncover insights into how moles change into melanomaon November 23, 2021 at 12:33 pm
Moles and melanomas are both skin tumors that come from the same cell called melanocytes. The difference is that moles are usually harmless, while melanomas are cancerous and often deadly without ...
- How moles change into melanomaon November 22, 2021 at 4:00 pm
Melanoma researchers published a study that gives a new explanation of what causes moles to change into melanoma. These findings pave the way for more research into how to reduce the risk of melanoma, ...
via Bing News
